BRCA1 and ovarian cancer: To ultimately define the role of UBE2T germline mutations in patients with breast/ovarian cancer, we performed whole exome sequencing using the Ilumina HiSeq platform on 450 BRCA1/2 WT high-risk breast cancer patients.